<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303377</url>
  </required_header>
  <id_info>
    <org_study_id>EXO_01</org_study_id>
    <secondary_id>2018-001065-17</secondary_id>
    <nct_id>NCT04303377</nct_id>
  </id_info>
  <brief_title>Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction</brief_title>
  <acronym>ExOTIC</acronym>
  <official_title>Early Treatment With evOlocumab in Patients With sT-elevation Myocardial Infarction Undergoing Primary pCi (ExOTIC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation IRCCS San Matteo Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Bassini Cinisello Balsamo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Ordine Mauriziano di Torino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Policlinico San Martino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Poliambulanza Istituto Ospedaliero</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Sant'Anna e San Sebastiano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera, Ospedale Civile di Legnano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation IRCCS San Matteo Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centre, open label, randomised study of Phase II that enrolls
      patients hospitalized with a diagnosis of ST-elevation myocardial infarction (STEMI),
      comparing Evolocumab versus Standard of Care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective of the study is to assess whether early evolocumab administration reduces
      infarct size in patients with STEMI undergoing primary PCI.

      At least 150 patients will be enrolled to investigate the efficacy and safety of evolocumab
      administration in the acute phase of STEMI.

      Patients will be followed for 1 year after the enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">November 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct Size reduces infarct size in patients with STEMI undergoing primary PCI</measure>
    <time_frame>6 months Visit</time_frame>
    <description>• Myocardial salvage index (MSI) at 6 months evaluated with cardiac magnetic resonance (CMR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Cytokine Response</measure>
    <time_frame>6 months Visit</time_frame>
    <description>Absolute changes of hs-C reactive protein, Interleukin 1, 6 and10, and alfa Tumor Necrosis Factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol LDL levels</measure>
    <time_frame>6 months Visit</time_frame>
    <description>Absolute and percentage changes in c-LDL levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>12 months Visit</time_frame>
    <description>Rate of composite cardiovascular death, MI or stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euroqol 5-dimension questionnaire</measure>
    <time_frame>12 months Visit</time_frame>
    <description>Euroqol 5-dimension questionnaire (minimum value 0, and maximum value 100)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>ST-elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Evolocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evolocumab administration in the acute phase of ST elevation myocardial infarction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Evolocumab 140 mg every 2 weeks plus Standard of Care, including optimal lipid lowering treatment (high dose of statin ± ezetimibe)</description>
    <arm_group_label>Evolocumab</arm_group_label>
    <other_name>Repatha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Chest pain or equivalent lasting &gt; 20 minutes

          -  ST elevation myocardial infarction scheduled for primary PCI

          -  Signed written informed consent

        Exclusion Criteria:

          -  Previous myocardial infarction

          -  Previous percutaneous or surgical myocardial revascularization

          -  Ongoing treatment with any statin or ezetimibe

          -  History of congestive heart failure

          -  Cardiogenic shock at presentation

          -  Known Pregnancy

          -  Women of Childbearing Age

          -  Known major active infection or major hematologic, renal, hepatic, or endocrine
             dysfunction

          -  Malignancy (except non-melanoma skin cancer, cervical in situ carcinoma, breast ductal
             carcinoma in situ, stage 1 prostate carcinoma) within the last 10 years

          -  Patients with hypersensitivity to the active substance (evolocumab) or to any of its
             excipients

          -  Inability to attend the scheduled clinical evaluation and laboratory tests

          -  Inability to undergo the pharmacological treatment or other procedures of the study

          -  Currently enrolled in another investigational drug study, or &lt; 30 days/&lt;5 half-life
             since ending another investigational drug study(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marco Ferlini, MD</last_name>
    <phone>+39 0382 503739</phone>
    <email>m.ferlini@smatteo.pv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Portolan, M.Sc.</last_name>
    <phone>+39 0382 503739</phone>
    <email>m.portolan@smatteo.pv.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Ferlini, MD</last_name>
      <phone>+39 0382 503739</phone>
      <email>m.ferlini@smatteo.pv.it</email>
    </contact>
    <contact_backup>
      <last_name>Monica Portolan, M.Sc</last_name>
      <phone>+39 0382 503739</phone>
      <email>m.portolan@smatteo.pv.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Foundation IRCCS San Matteo Hospital</investigator_affiliation>
    <investigator_full_name>Marco Ferlini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Evolocumab</keyword>
  <keyword>Cardiac Magnetic Resonance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

